News > Early treatment with Favipiravir shows faster viral clearance in mild Covid-19 cases

Early treatment with Favipiravir shows faster viral clearance in mild Covid-19 cases

Favipiravir, an oral antiviral drug approved for the treatment of Covid-19 in Japan and China, may be safe and effective for mild to moderate cases. Treatment with this drug has led to significant improvement in the time taken for the infection to be cured, as per results of the first-ever randomised controlled trial of the drug.

Favipiravir is an oral RNA-dependent RNA polymerase inhibitor, and the drug is under investigation in many countries for the treatment of Covid-19.